AMA1-DiCo sponsored students

Muzamil Mahdi Abdel Hamid

Funded under the EVI supported AMA1-DiCo project.

Based at: Biomedical Primate Research Centre (BPRC) Rijswijk and Institute of Endemic Diseases, University of Khartoum

Supervisors: Prof. Alan W. Thomas (PhD) and Dr. Bart W. Faber (PhD), BPRC, Rijsvijk

Supervisors: Dr. Ibrahim M. El Hassan (PhD), Institute of Endemic Diseases, University of Khartoum


Development of the Plasmodium knowlesi Rhesus Macaque Model Using the Malaria Vaccine Candidate Apical Membrane Antigen 1 (AMA1) ( University of  Khartoum, Sudan, September 2009).

The main objectives of the present study were:

  1. to produce good quality recombinant apical membrane antigen 1 (AMA1) using Pichia pastoris expression system
  2. to evaluate the efficacy, immunogenicity, and safety of AMA1 subunit vaccine
  3. to assess the correlation between antibody titers and protection
  4. to define the immune responses governing efficacy of Pk4 DNA prime/pox viral boost vaccine and whether it correlates with protection against malaria
  5. to setup a challenge model to evaluate future malaria vaccine candidates and adjuvants.

Muzamil Mahdi Abdel Hamid was born in Atbara, the northern state, Sudan in 1973.  In 1998 he obtained a Bachelor degree in Veterinary Science followed by a Master degree in Molecular Biology in 2002 at the University of Khartoum.

Kwadwo Asamoah Kusi

Funded in part by the EVI supported European Malaria Vaccine Development Association (EMVDA) and AMA1-DiCo project.

Based at: Biomedical Primate Research Centre (BPRC) Rijswijk

Promotor: Prof.dr. A.M. Deelder

Co-promotor: Dr. C.H.M. Kocken, BPRC, Rijswijk

Co-promotor: Dr. E.J. Remarque, BPRC, Rijswijk

Towards a blood stage malaria vaccine, dealing with allelic polymorphism in the vaccine candidate apical membrane antigen. 1 (Leiden University, the Netherlands ,January 2012).

This thesis investigated multi-allele vaccine formulation strategies that would overcome the strain-specificity of antibody responses to PfAMA1.  The main findings of this thesis are that i) different PfAMA1 alleles share epitopes to which functional cross-strain antibodies can be induced, ii) a three-allele PfAMA1 formulation yields the greatest proportion of functional cross-strain antibodies, and iii) three PfAMA1 alleles, irrespective of the adjuvant used for formulation and whether they are administrated as a multi-allele formulation or sequentially, induce similar proportions of cross-strain antibodies.  Overall, a multi-allele formulation with three in silico-designed PfAMA1 candidates yields antibodies that inhibit several parasites in vitro and warrant their development as a human blood stage vaccine.

Kwadwo Asamoah Kusi was born in Accra, Ghana in 1977.  In 2005 he obtained a  

Masters degree in biochemistry from the University of Ghana, Legon.